Ciprofibrate

Summary

Ciprofibrate (CHEMBL557555) is an approved small-molecule antilipemic drug (ATC C10AB08) targeting PPARA; indicated across 1 condition including cardiovascular disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: C10AB08
• Targets: 1 (PPARA)
• Indications: 1 condition
• Clinical trials: 3
• Chemistry: 289.15 Da · C13H14Cl2O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL557555
Name	Ciprofibrate
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	2763
ChEBI	CHEBI:50867
ATC	C10AB08
Molecular formula	C13H14Cl2O3
Molecular weight	289.15
InChIKey	KPSRODZRAIWAKH-UHFFFAOYSA-N

SMILES: CC(C)(C(=O)O)OC1=CC=C(C=C1)C2CC2(Cl)Cl

IUPAC name: 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanoic acid

Pharmacological roles (ChEBI): antilipemic drug.

Also known as: Ciprofibrate, Ciprofibrato, Modalim, NSC-759617, WIN 35833, WIN-35833, SID26757866, SID50105908, SID56463556, SID90340632, ciprofibrate, SID85230953

Patent coverage: 2,847 distinct patent families (11,386 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
PPARA	Peroxisome proliferator-activated receptor-α	Agonist	6.05	0.7%	Q07869

Broader ChEMBL bioactivity targets: 4 (assay-derived). Sample: Prelamin-A/C, RecQ-like DNA helicase BLM, Beta-lactamase, Peroxisome proliferator-activated receptor alpha.

Bioactivity

ChEMBL activities: 5 potent at pChembl ≥ 5 of 7 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
PPARA	6.05	EC50	900	nM	CHEMBL_ACT_10848094
PPARA	6.05	EC50	900	nM	CHEMBL_ACT_12066458
LMNA	5.55	Potency	2818	nM	CHEMBL_ACT_3667755
P00811	5.3	Potency	5012	nM	CHEMBL_ACT_4746357
LMNA	5.25	Potency	5623	nM	CHEMBL_ACT_3626253

Target pathways

Aggregated over 1 target gene(s): PPARA.

Top Reactome pathways

13 total, by targets touching each:

Pathway	Targets	Genes
BMAL1:CLOCK,NPAS2 activates circadian expression	1	PPARA
PPARA activates gene expression	1	PPARA
Transcriptional activation of mitochondrial biogenesis	1	PPARA
Activation of gene expression by SREBF (SREBP)	1	PPARA
Transcriptional regulation of white adipocyte differentiation	1	PPARA
Nuclear Receptor transcription pathway	1	PPARA
Regulation of lipid metabolism by PPARalpha	1	PPARA
SUMOylation of intracellular receptors	1	PPARA
Cytoprotection by HMOX1	1	PPARA
Heme signaling	1	PPARA
Transcriptional regulation of brown and beige adipocyte differentiation by EBF2	1	PPARA
Expression of BMAL (ARNTL), CLOCK, and NPAS2	1	PPARA
RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression	1	PPARA

Dominant GO biological processes

GO term	Targets
negative regulation of transcription by RNA polymerase II	1
response to hypoxia	1
gluconeogenesis	1
fatty acid metabolic process	1
heart development	1
response to nutrient	1
lactation	1
epidermis development	1
cellular response to starvation	1
hormone-mediated signaling pathway	1
gene expression	1
regulation of ketone metabolic process	1
negative regulation of macrophage derived foam cell differentiation	1
negative regulation of cholesterol storage	1
protein ubiquitination	1

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
cardiovascular disorder	4	MONDO:0004995	EFO:0000319

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE4	2
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00350038	PHASE4	COMPLETED	Irbesartan, Ciprofibrate and Their Combination Onto the Endothelial Functions
NCT01480687	PHASE4	UNKNOWN	Fish Oil Supplementation and Vascular Function in Hypertensive Patients With Hypertriglyceridemia
NCT06858332	Not specified	RECRUITING	Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

37 molecules share ≥1 primary target. Top 37 by shared-target count:

Molecule	Source	Status	Shared targets
SELADELPAR	ChEMBL + PubChem	Phase 4 (approved)	PPARA
BERBERINE	ChEMBL	Phase 4 (approved)	PPARA
CLOFIBRATE	ChEMBL	Phase 4 (approved)	PPARA
CYCLOSPORINE	ChEMBL	Phase 4 (approved)	PPARA
ELAFIBRANOR	ChEMBL	Phase 4 (approved)	PPARA
FENOFIBRATE	ChEMBL	Phase 4 (approved)	PPARA
FENOFIBRIC ACID	ChEMBL	Phase 4 (approved)	PPARA
GEMFIBROZIL	ChEMBL	Phase 4 (approved)	PPARA
PEMAFIBRATE	ChEMBL	Phase 4 (approved)	PPARA
PIOGLITAZONE	ChEMBL	Phase 4 (approved)	PPARA
RACECADOTRIL	ChEMBL	Phase 4 (approved)	PPARA
ROSIGLITAZONE	ChEMBL	Phase 4 (approved)	PPARA
ALEGLITAZAR	ChEMBL	Phase 3	PPARA
BEZAFIBRATE	ChEMBL	Phase 3	PPARA
GAMOLENIC ACID	ChEMBL	Phase 3	PPARA
ICOSAPENT	ChEMBL	Phase 3	PPARA
IMIGLITAZAR	ChEMBL	Phase 3	PPARA
LANIFIBRANOR	ChEMBL	Phase 3	PPARA
LOBEGLITAZONE	ChEMBL	Phase 3	PPARA
MURAGLITAZAR	ChEMBL	Phase 3	PPARA
TESAGLITAZAR	ChEMBL	Phase 3	PPARA
CLOFIBRIC ACID	ChEMBL	Phase 2	PPARA
DIHOMO-GAMMA-LINOLENIC ACID	ChEMBL	Phase 2	PPARA
FARGLITAZAR	ChEMBL	Phase 2	PPARA
GW501516	ChEMBL	Phase 2	PPARA
GW590735	ChEMBL	Phase 2	PPARA
INDEGLITAZAR	ChEMBL	Phase 2	PPARA
LINOLEIC ACID	ChEMBL	Phase 2	PPARA
LY-518674	ChEMBL	Phase 2	PPARA
NAVEGLITAZAR	ChEMBL	Phase 2	PPARA
OLEIC ACID	ChEMBL	Phase 2	PPARA
PIRINIXIC ACID	ChEMBL	Phase 2	PPARA
RAGAGLITAZAR	ChEMBL	Phase 2	PPARA
REGLITAZAR	ChEMBL	Phase 2	PPARA
URSOLIC ACID	ChEMBL	Phase 2	PPARA
Bosentan	PubChem	Approved	PPARA
regorafenib	PubChem	Approved	PPARA